Biogen. Every tracked FinTwit mention of $BIIB, newest first. 10 mentions since the first on Dec 15, 2025. See the price chart.
July 2026 · 3 mentions
Jul 16
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter:
I chatted with $AMLX co-CEOs Johua Cohen and Justin Klee about avexitide, their GLP-1 ANTAGONIST nearing read out of a pivotal study in a…↗
Jul 14
Adam Feuerstein ✡️ — $BIIB tau drug results just revealed at #AAIC26
Diranersen slowed cognitive decline as 26% compared to a placebo, in line with efficacy shown by currently approved amyloid drugs.…↗
Jul 12
Adam Feuerstein ✡️ — My London colleague @DrewQJoseph is attending #AAIC26. Here's his first report: A preview of $BIIB 's tau-targeting drug study that will be presented on Tuesday. Plus:
🧠Alzheime…↗
May 2026 · 1 mention
May 14
Adam Feuerstein ✡️ — $BIIB Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
Diranersen (BIIB080) reduced tau and slowed cognitive decline but Biogen is not disclosing de…↗
April 2026 · 1 mention
Apr 3
Special Situation Investments — Biogen is making a major move in rare disease.
- $APLS to be acquired by $BIIB
- $41.00/sh cash + $4.00 CVR
- Tiny spread to cash + "free option" CVR
- ~14% shareholder support al…↗
March 2026 · 4 mentions
Mar 31
Adam Feuerstein ✡️ — Biogen $BIIB to acquire immunology biotech Apellis $APLS for $5.6 billion https://t.co/07hf3RyfZG via @elaineywchen↗
InvestmentGuru — $QNTM – From Speculative Microcap to Multi-Catalyst Biotech Story Unfolding
Over the past week, $QNTM has quietly delivered a series of developments that signal a clear transition…↗
Mar 6
Jacob Plieth — $DAWN acquisition by Servier for $2.5bn is quite the ending for Ojemda. Who remembers this RAF inhibitor's bizarre & convoluted history? $BIIB $TAK https://t.co/uD5drO9ymr